Glutamate and its receptors in cancer

Journal of Neural Transmission

Volumn 121, Issue 8, 2014, Pages 933-944

  Stepulak, Andrzej ^a,b   Rola, Radoslaw ^a,c   Polberg, Krzysztof ^b   Ikonomidou, Chrysanthy ^d  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MSW Hospital   (Poland)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cancer; Glutamate receptor; Growth factor; Prognosis

Indexed keywords

AMPA RECEPTOR; CHLORPHENIRAMINE MALEATE PLUS PHENYLEPHRINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR;

ARTICLE; CANCER CELL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; ANIMAL; METABOLISM;

ANIMALS; GLUTAMIC ACID; HUMANS; NEOPLASMS; RECEPTORS, GLUTAMATE;

EID: 84925779348     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1182-6     Document Type: Article

References (100)

1. Abdul M, Hoosein N (2005) N-methyl-D-aspartate receptor in human prostate cancer. J Membr Biol 205(3):125-128. doi:10.1007/s00232-005-0777-0
2. Albasanz JL, Ros M, Martin M (1997) Characterization of metabotropic glutamate receptors in rat C6 glioma cells. Eur J Pharmacol 326(1):85-91
3. Aronica E, Yankaya B, Jansen GH, Leenstra S, van Veelen CW, Gorter JA, Troost D (2001) Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol 27(3):223-237
4. Beretta F, Bassani S, Binda E, Verpelli C, Bello L, Galli R, Passafaro M (2009) The GluR2 subunit inhibits proliferation by inactivating Src-MAPK signalling and induces apoptosis by means of caspase 3/6-dependent activation in glioma cells. Eur J Neurosci 30(1):25-34. doi:10.1111/j.1460-9568.2009.06804.x
5. Brocke KS, Staufner C, Luksch H, Geiger KD, Stepulak A, Marzahn J, Schackert G, Temme A, Ikonomidou C (2010) Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 9(6):455-468
6. Broderick PA, Doyle WK, Pacia SV, Kuznieck RI, Devinsky O, Kolodny EH (2008) A clinical trial of an advanced diagnostic biomedical device for epilepsy patients. J Long-Term Eff Med Implant 18(1)
7. Burnashev N, Monyer H, Seeburg PH, Sakmann B (1992) Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron 8(1):189-198
8. Casado M, Lopez-Guajardo A, Mellstrom B, Naranjo JR, Lerma J (1996) Functional N-methyl-D-aspartate receptors in clonal rat phaeochromocytoma cells. J Physiol 490(Pt 2):391-404
9. Chang HJ, Yoo BC, Lim SB, Jeong SY, Kim WH, Park JG (2005) Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res Off J Am Assoc Cancer Res 11(9):3288-3295. doi:10.1158/1078-0432.CCR-04-1912
10. Choi SW, Park SY, Hong SP, Pai H, Choi JY, Kim SG (2004) The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol 33(9):533-537. doi:10.1111/j.1600-0714.2004.00226.x
11. Choi KY, Chang K, Pickel JM, Badger JD 2nd, Roche KW (2011) Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice. Proc Natl Acad Sci USA 108(37):15219-15224. doi:10.1073/pnas.1107304108
12. Choi CH, Choi JJ, Park YA, Lee YY, Song SY, Sung CO, Song T, Kim MK, Kim TJ, Lee JW, Kim HJ, Bae DS, Kim BG (2012) Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival. Br J Cancer 107(1):91-99. doi:10.1038/bjc.2012.217
13. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci Off J Soc Neurosci 25(31):7101-7110. doi:10.1523/JNEUROSCI.5258-04.2005
14. Ciceroni C, Arcella A, Mosillo P, Battaglia G, Mastrantoni E, Oliva MA, Carpinelli G, Santoro F, Sale P, Ricci-Vitiani L, De Maria R, Pallini R, Giangaspero F, Nicoletti F, Melchiorri D (2008) Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. Neuropharmacology 55(4):568-576. doi:10.1016/j.neuropharm.2008.06.064
15. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K (2010) A multigene predictor of outcome in glioblastoma. Neuro-oncology 12(1):49-57. doi:10.1093/neuonc/nop007
16. Condorelli DF, Dell'Albani P, Corsaro M, Giuffrida R, Caruso A, Trovato Salinaro A, Spinella F, Nicoletti F, Albanese V, Giuffrida Stella AM (1997) Metabotropic glutamate receptor expression in cultured rat astrocytes and human gliomas. Neurochem Res 22(9):1127-1133
17. Contractor A, Mulle C, Swanson GT (2011) Kainate receptors coming of age: milestones of two decades of research. Trends Neurosci 34(3):154-163. doi:10.1016/j.tins.2010.12.002
18. Cull-Candy S, Brickley S, Farrant M (2001) NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11(3):327-335
19. de Groot J, Sontheimer H (2011) Glutamate and the biology of gliomas. Glia 59(8):1181-1189. doi:10.1002/glia.21113
20. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK (2008) Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol 88(2):121-133. doi:10.1007/s11060-008-9552-2
21. DiRaddo JO, Pshenichkin S, Gelb T, Wroblewski JT (2013) Two newly identified exons in human GRM1 express a novel splice variant of metabotropic glutamate 1 receptor. Gene 519(2): 367-373. doi:10.1016/j.gene.2013.02.009
22. Esseltine JL, Willard MD, Wulur IH, Lajiness ME, Barber TD, Ferguson SS (2013) Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling. Mol Pharmacol 83(4):770-780. doi:10.1124/mol.112.081695
23. Ganor Y, Grinberg I, Reis A, Cooper I, Goldstein RS, Levite M (2009) Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147/EMMPRIN, MMP-9 secretion and engraftment of T-leukemia in vivo. Leuk Lymphoma 50(6):985-997. doi:10.1080/10428190902878448
24. Hechtman JF, Xiao GQ, Unger PD, Kinoshita Y, Godbold JH, Burstein DE (2012) Anti-glutamate receptor 2 as a new potential diagnostic probe for prostatic adenocarcinoma: a pilot immunohistochemical study. Appl Immunohistochem Mol Morphol AIMM/Off Publ Soc Appl Immunohistochem 20(4):344-349. doi:10.1097/PAI.0b013e31824013ba
25. Herner A, Sauliunaite D, Michalski CW, Erkan M, De Oliveira T, Abiatari I, Kong B, Esposito I, Friess H, Kleeff J (2011) Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Int J Cancer J Int du Cancer 129(10):2349-2359. doi:10.1002/ijc.25898
26. Hinoi E, Takarada T, Ueshima T, Tsuchihashi Y, Yoneda Y (2004) Glutamate signaling in peripheral tissues. Eur J Biochem/FEBS 271(1):1-13
27. Hollmann M, Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31-108. doi:10.1146/annurev.ne.17.030194.000335
28. Iacovelli L, Arcella A, Battaglia G, Pazzaglia S, Aronica E, Spinsanti P, Caruso A, De Smaele E, Saran A, Gulino A, D'Onofrio M, Giangaspero F, Nicoletti F (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci Off J Soc Neurosci 26(32):8388-8397. doi:10.1523/JNEUROSCI.2285-06.2006
29. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283(5398):70-74
30. Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H, Miwa A, Kurihara H, Nakazato Y, Tamura M, Sasaki T, Ozawa S (2002) Blockage of Ca(2?)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8(9):971-978. doi:10.1038/nm746
31. Kalariti N, Lembessis P, Koutsilieris M (2004) Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res 24(6):3923-3929
32. Kalariti N, Pissimissis N, Koutsilieris M (2005) The glutamatergic system outside the CNS and in cancer biology. Expert Opin Investig Drugs 14(12):1487-1496. doi:10.1517/13543784.14.12.1487
33. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466(7308):869-873. doi:10.1038/nature09208
34. Kew JN, Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179(1):4-29. doi:10.1007/s00213-005-2200-z
35. Kim MS, Yamashita K, Baek JH, Park HL, Carvalho AL, Osada M, Hoque MO, Upadhyay S, Mori M, Moon C, Sidransky D (2006) N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 66(7):3409-3418. doi:10.1158/0008-5472.CAN-05-1608
36. Kim MS, Chang X, Nagpal JK, Yamashita K, Baek JH, Dasgupta S, Wu G, Osada M, Woo JH, Westra WH, Trink B, Ratovitski EA, Moon C, Sidransky D (2008) The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Oncogene 27(14):2045-2054. doi:10.1038/sj.onc.1210842
37. Komuro H, Rakic P (1993) Modulation of neuronal migration by NMDA receptors. Science 260(5104):95-97
38. Koochekpour S (2013) Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer. Asian J Androl 15(2):212-213. doi:10.1038/aja.2012.145
39. Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, Manhardt C, Lorusso GD, Willard SS, Thompson H, Shourideh M, Rezaei K, Sartor O, Mohler JL, Vessella RL (2012) Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res Off J Am Assoc Cancer Res 18(21):5888-5901. doi:10.1158/1078-0432.CCR-12-1308
40. Korczak B, McWhinnie EA, Fletcher EJ, Kamboj RK (1995) Expression of human glutamate receptors (GluR) in neuroblastoma cell lines. NeuroReport 6(6):905-909
41. Labrakakis C, Patt S, Hartmann J, Kettenmann H (1998) Glutamate receptor activation can trigger electrical activity in human glioma cells. Eur J Neurosci 10(6):2153-2162
42. Lau A, Tymianski M (2010) Glutamate receptors, neurotoxicity and neurodegeneration. Pflug Arch 460(2):525-542. doi:10.1007/s00424-010-0809-1
43. Li L, Hanahan D (2013) Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell 153(1):86-100. doi:10.1016/j.cell.2013.02.051
44. Li S, Qian J, Yang Y, Zhao W, Dai J, Bei JX, Foo JN, McLaren PJ, Li Z, Yang J, Shen F, Liu L, Yang J, Li S, Pan S, Wang Y, Li W, Zhai X, Zhou B, Shi L, Chen X, Chu M, Yan Y, Wang J, Cheng S, Shen J, Jia W, Liu J, Yang J, Wen Z, Li A, Zhang Y, Zhang G, Luo X, Qin H, Chen M, Wang H, Jin L, Lin D, Shen H, He L, de Bakker PI, Wang H, Zeng YX, Wu M, Hu Z, Shi Y, Liu J, Zhou W (2012) GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 8(7):e1002791. doi:10.1371/journal. pgen.1002791
45. Liu JW, Kim MS, Nagpal J, Yamashita K, Poeta L, Chang X, Lee J, Park HL, Jeronimo C, Westra WH, Mori M, Moon C, Trink B, Sidransky D (2007) Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int J Cancer J Int du Cancer 121(9):1994-2000. doi:10.1002/ijc.22934
46. Luksch H, Uckermann O, Stepulak A, Hendruschk S, Marzahn J, Bastian S, Staufner C, Temme A, Ikonomidou C (2011) Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res 31(10):3181-3192
47. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H (2007) Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 67(19):9463-9471. doi:10.1158/0008-5472.CAN-07-2034
48. Maas S, Patt S, Schrey M, Rich A (2001) Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci USA 98(25):14687-14692. doi:10.1073/pnas.251531398
49. Marin YE, Chen S (2004) Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. J Mol Med 82(11):735-749. doi:10.1007/s00109-004-0566-8
50. Martino JJ, Wall BA, Mastrantoni E, Wilimczyk BJ, La Cava SN, Degenhardt K, White E, Chen S (2013) Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene 32(37):4366-4376. doi:10.1038/onc.2012.471
51. Mayer ML (2005) Glutamate receptor ion channels. Curr Opin Neurobiol 15(3):282-288. doi:10.1016/j.conb.2005.05.004
52. Mehta MS, Dolfi SC, Bronfenbrener R, Bilal E, Chen C, Moore D, Lin Y, Rahim H, Aisner S, Kersellius RD, Teh J, Chen S, Toppmeyer DL, Medina DJ, Ganesan S, Vazquez A, Hirshfield KM (2013) Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. PLoS One 8(7):e69851. doi:10.1371/journal.pone.0069851
53. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D (2007) Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci 28(5):206-213. doi:10.1016/j.tips.2007.03.008
54. North WG, Fay MJ, Du J, Cleary M, Gallagher JD, McCann FV (1997) Presence of functional NMDA receptors in a human neuroblastoma cell line. Mol Chem Neuropathol/Spons Int Soc Neurochem World Fed Neurol Res Groups Neurochem Cerebrospinal Fluid 30(1-2):77-94
55. North WG, Gao G, Jensen A, Memoli VA, Du J (2010a) NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment. Clin Pharmacol Adv Appl 2:31-40. doi:10.2147/CPAA.S6262
56. North WG, Gao G, Memoli VA, Pang RH, Lynch L (2010b) Breast cancer expresses functional NMDA receptors. Breast Cancer Res Treat 122(2):307-314. doi:10.1007/s10549-009-0556-1
57. Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W (2002) The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wien Klin Wochenschr 114(21-22):911-916
58. Oh MC, Kim JM, Safaee M, Kaur G, Sun MZ, Kaur R, Celli A, Mauro TM, Parsa AT (2012) Overexpression of calciumpermeable glutamate receptors in glioblastoma derived brain tumor initiating cells. PLoS One 7(10):e47846. doi:10.1371/journal.pone.0047846
59. Ohkuma S, Katsura M, Chen DZ, Chen SH, Kuriyama K (1994) Presence of N-methyl-D-aspartate (NMDA) receptors in neuroblastoma x glioma hybrid NG108-15 cells-analysis using [45Ca2?]influx and [3H]MK-801 binding as functional measures. Brain Res Mol Brain Res 22(1-4):166-172
60. Ohtani Y, Harada T, Funasaka Y, Nakao K, Takahara C, Abdel-Daim M, Sakai N, Saito N, Nishigori C, Aiba A (2008) Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 27(57):7162-7170. doi:10.1038/onc.2008. 329
61. Ortiz P, Vanaclocha F, Lopez-Bran E, Esquivias JI, Lopez-Estebaranz JL, Martin-Gonzalez M, Arrue I, Garcia-Romero D, Ochoa C, Gonzalez-Perez A, Ruiz A, Real LM (2007) Genetic analysis of the GRM1 gene in human melanoma susceptibility. Eur J Hum Genet EJHG 15(11):1176-1182. doi:10.1038/sj.ejhg.5201887
62. Palmer CL, Cotton L, Henley JM (2005) The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 57(2):253-277. doi:10.1124/pr.57.2.7
63. Park SY, Lee SA, Han IH, Yoo BC, Lee SH, Park JY, Cha IH, Kim J, Choi SW (2007) Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 17(1):81-87
64. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH (2011) Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch Int J Pathol 458(1):73-84. doi:10.1007/s00428-010-1013-6
65. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807-1812. doi:10.1126/science.1164382
66. Peng S, Zhang Y, Zhang J, Wang H, Ren B (2011) Glutamate receptors and signal transduction in learning and memory. Mol Biol Rep 38(1):453-460. doi:10.1007/s11033-010-0128-9
67. Pissimissis N, Papageorgiou E, Lembessis P, Armakolas A, Koutsilieris M (2009) The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res 29(1):371-377
68. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, Zhu H, Robbins C, Makalowska I, Shin SS, Marin Y, Roberts KG, Yudt LM, Chen A, Cheng J, Incao A, Pinkett HW, Graham CL, Dunn K, Crespo-Carbone SM, Mackason KR, Ryan KB, Sinsimer D, Goydos J, Reuhl KR, Eckhaus M, Meltzer PS, Pavan WJ, Trent JM, Chen S (2003) Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 34(1):108-112. doi:10.1038/ng1148
69. Prickett TD, Samuels Y (2012) Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18(16):4240-4246. doi:10.1158/1078-0432.CCR-11-1217
70. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels Y (2011) Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43(11):1119-1126. doi:10.1038/ng.950
71. Ripka S, Riedel J, Neesse A, Griesmann H, Buchholz M, Ellenrieder V, Moeller F, Barth P, Gress TM, Michl P (2010) Glutamate receptor GRIA3-target of CUX1 and mediator of tumor progression in pancreatic cancer. Neoplasia 12(8):659-667
72. Rothstein JD, Brem H (2001) Excitotoxic destruction facilitates brain tumor growth. Nat Med 7(9):994-995. doi:10.1038/nm0901-994
73. Rzeski W, Turski L, Ikonomidou C (2001) Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98(11):6372-6377. doi:10.1073/pnas.091113598
74. Seeburg PH (1993) The TINS/TiPS Lecture. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci 16(9):359-365
75. Seidlitz EP, Sharma MK, Saikali Z, Ghert M, Singh G (2009) Cancer cell lines release glutamate into the extracellular environment. Clin Exp Metastasis 26(7):781-787. doi:10.1007/s10585-009-9277-4
76. Shin SS, Namkoong J, Wall BA, Gleason R, Lee HJ, Chen S (2008) Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res 21(3):368-378. doi:10.1111/j.1755-148X.2008.00452.x
77. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314(5797): 268-274. doi:10.1126/science.1133427
78. Sontheimer H (2008) A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 105(2):287-295. doi:10.1111/j.1471-4159.2008.05301.x
79. Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH (2012) Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 132(2):565-573. doi:10.1007/s10549-011-1624-x
80. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U, Kaindl AM, Buhrer C, Hansen HH, Stryjecka-Zimmer M, Turski L, Ikonomidou C (2005) NMDA antagonist inhibits the extracellular signalregulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 102(43):15605-15610. doi:10.1073/pnas.0507679102
81. Stepulak A, Sifringer M, Rzeski W, Brocke K, Gratopp A, Pohl EE, Turski L, Ikonomidou C (2007) AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther 6(12):1908-1915
82. Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M, Rzeski W, Staufner C, Brocke KS, Turski L, Ikonomidou C (2009) Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132(4):435-445. doi:10.1007/s00418-009-0613-1
83. Stepulak A, Luksch H, Uckermann O, Sifringer M, Rzeski W, Polberg K, Kupisz K, Klatka J, Kielbus M, Grabarska A, Marzahn J, Turski L, Ikonomidou C (2011) Glutamate receptors in laryngeal cancer cells. Anticancer Res 31(2):565-573
84. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7(9):1010-1015. doi:10.1038/nm0901-1010
85. Takeda M, Haga M, Yamada H, Kinoshita M, Otsuka M, Tsuboi S, Moriyama Y (2000) Ionotropic glutamate receptors expressed in human retinoblastoma Y79 cells. Neurosci Lett 294(2):97-100
86. Tamura H, Suzuki M, Moriya Y, Hoshino H, Okamoto T, Yoshida S, Yoshino I (2011) Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma. BMC Cancer 11:220. doi:10.1186/1471-2407-11-220
87. Teh J, Chen S (2012) mGlu receptors and cancerous growth. Wiley Interdiscip Rev Membr Transp Signal 1(2):211-220. doi:10.1002/wmts.21
88. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62(3):405-496. doi:10.1124/pr.109.002451
89. Virani S, Colacino JA, Kim JH, Rozek LS (2012) Cancer epigenetics: a brief review. ILAR J/Natl Res Counc, Inst Lab Anim Resour 53(3-4):359-369. doi:10.1093/ilar.53.3-4.359
90. Watanabe K, Kanno T, Oshima T, Miwa H, Tashiro C, Nishizaki T (2008) The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells. Biochem Biophys Res Commun 367(2):487-490. doi:10.1016/j.bbrc.2007.12.167
91. Waxman EA, Lynch DR (2005) N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry 11(1):37-49. doi:10.1177/1073858404269012
92. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Program NCS, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y (2011) Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43(5):442-446. doi:10.1038/ng.810
93. Willard SS, Koochekpour S (2013) Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. Int J Biol Sci 9(7):728-742. doi:10.7150/ijbs.6475
94. Wu J, Xu L, Kim DY, Rho JM, St John PA, Lue LF, Coons S, Ellsworth K, Nowak L, Johnson E, Rekate H, Kerrigan JF (2005) Electrophysiological properties of human hypothalamic hamartomas. Ann Neurol 58(3):371-382. doi:10.1002/ana.20580
95. Wu CS, Lu YJ, Li HP, Hsueh C, Lu CY, Leu YW, Liu HP, Lin KH, Hui-Ming Huang T, Chang YS (2010) Glutamate receptor, ionotropic, kainate 2 silencing by DNA hypermethylation possesses tumor suppressor function in gastric cancer. Int J Cancer J Int du Cancer 126(11):2542-2552. doi:10.1002/ijc. 24958
96. Yamaguchi F, Hirata Y, Akram H, Kamitori K, Dong Y, Sui L, Tokuda M (2013) FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801. BMC Cancer 13(1):468. doi:10.1186/1471-2407-13-468
97. Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59(17):4383-4391
98. Yoo BC, Jeon E, Hong SH, Shin YK, Chang HJ, Park JG (2004) Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line. Clin Cancer Res Off J Am Assoc Cancer Res 10(12 Pt 1):4176-4184. doi:10.1158/1078-0432.CCR-1114-03
99. Yoshida Y, Tsuzuki K, Ishiuchi S, Ozawa S (2006) Serumdependence of AMPA receptor-mediated proliferation in glioma cells. Pathol Int 56(5):262-271. doi:10.1111/j.1440-1827.2006.01954.x
100. Yoshioka A, Ikegaki N, Williams M, Pleasure D (1996) Expression of N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptor genes in neuroblastoma, medulloblastoma, and other cells lines. J Neurosci Res 46(2):164-178. doi:10.1002/(SICI)1097-4547(19961015)46:2\164:AID-JNR4[3.0.CO;2-F